Baird Financial Group Inc. Sells 4,744 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Baird Financial Group reduced its Regeneron stake by 8.2%, selling 4,744 shares and retaining 52,845 shares valued at approximately $33 million. Institutional investors collectively own 83.31% of the company.
• Regeneron reported a strong quarter, with EPS of $14.29 versus the $10.16 consensus estimate and revenue of $4.29 billion, up 16.7% year over year. The company also declared a quarterly dividend of $0.94 per share, yielding about 0.5%.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and an average price target of $802.18, although investors should note insider selling and a securities class-action lawsuit related to alleged disclosures surrounding the Fianlimab-Libtayo trial.

Baird Financial Group Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 52,845 shares of the biopharmaceutical company's stock after selling 4,744 shares during the quarter. Baird Financial Group Inc. owned approximately 0.05% of Regeneron Pharmaceuticals worth $32,951,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $226,000. Arrowstreet Capital Limited Partnership bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $3,183,000. Gabelli Funds LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company's stock worth $978,000 after buying an additional 55 shares during the period. Finally, Sei Investments Co. grew its stake in shares of Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company's stock worth $16,985,000 after acquiring an additional 5,120 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $793.26 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business's 50 day simple moving average is $752.38 and its 200 day simple moving average is $720.15. The stock has a market capitalization of $81.67 billion, a PE ratio of 19.61, a PEG ratio of 1.58 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $12.81 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: HSBC raised its price target to $920 from $800 and maintained a Buy rating, implying additional upside based on the firm’s assessment of Regeneron’s prospects. HSBC price-target report
• Neutral Sentiment: A Wells Fargo healthcare-conference presentation and transcript offered investors additional management commentary, though the provided report does not identify a specific new catalyst. Wells Fargo healthcare conference transcript
• Neutral Sentiment: A report showing zero short interest is likely incomplete or erroneous, because it also reports a zero-day short-interest ratio and an undefined percentage change; it provides little actionable information for investors.
• Negative Sentiment: Several law firms repeated notices about a securities class action against Regeneron, with a September 14, 2026 lead-plaintiff deadline. The lawsuit concerns alleged failures to disclose risks surrounding the Phase 3 Fianlimab-Libtayo trial for melanoma, including statistical and protocol issues and possible effects of FDA Optimus-related amendments on progression-free-survival analysis. The allegations have not been proven. REGN class-action deadline notice
• Negative Sentiment: Reports that American Century Investments sold Regeneron shares may add to concerns about institutional conviction, although the available coverage does not provide the size or timing of the sale. American Century Investments sale report

Wall Street Analyst Weigh In

Several research firms have weighed in on REGN. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a report on Thursday, July 9th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research report on Monday, May 18th. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Finally, Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Fourteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $802.18.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director directly owned 603 shares of the company's stock, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,146 shares of company stock valued at $3,432,488 in the last 90 days. Corporate insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.